Inmune Bio (INMB) Director James Sapirstein Receives Award

What Happened
James Sapirstein, a director of Inmune Bio, was granted a derivative award of 100,000 shares (reported as acquisition A) on 2026-09-15. The Form 4 reports an acquisition price of $0.00 (total reported value $0), indicating a stock option award rather than an immediate purchase of common shares.

Key Details

• Transaction date: 2026-09-15; Form 4 filed: 2026-09-17 (timely filing).
• Transaction type: Award/Grant (derivative) — 100,000 options reported as acquired at $0.00.
• Vesting: Options vest in 36 equal monthly installments (1/36 per month) beginning one month after grant, fully vesting on the three‑year anniversary. (Footnote: granted under the Issuer's Third Amended and Restated 2021 Stock Incentive Plan.)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing status: No late filing indicated based on dates provided.

Context
This was a compensation grant of stock options to a director, not an open‑market purchase or sale. The award does not represent immediately tradable shares — the options must vest (and typically be exercised) before becoming common stock. Such director option grants are common and should be viewed as compensation rather than a direct signal of immediate buying or selling.